CN110123749B - 尼可地尔脂微球制剂及其制备方法 - Google Patents
尼可地尔脂微球制剂及其制备方法 Download PDFInfo
- Publication number
- CN110123749B CN110123749B CN201910475456.6A CN201910475456A CN110123749B CN 110123749 B CN110123749 B CN 110123749B CN 201910475456 A CN201910475456 A CN 201910475456A CN 110123749 B CN110123749 B CN 110123749B
- Authority
- CN
- China
- Prior art keywords
- nicorandil
- injection
- oil
- preparation
- oil phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002497 nicorandil Drugs 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 239000004005 microsphere Substances 0.000 title claims abstract description 40
- -1 Nicorandil lipid Chemical class 0.000 title claims abstract description 35
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims abstract description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 55
- 238000002347 injection Methods 0.000 claims abstract description 33
- 239000007924 injection Substances 0.000 claims abstract description 33
- 239000008215 water for injection Substances 0.000 claims abstract description 25
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 24
- 239000002245 particle Substances 0.000 claims abstract description 16
- 239000003921 oil Substances 0.000 claims description 89
- 235000019198 oils Nutrition 0.000 claims description 89
- 239000003814 drug Substances 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 30
- 239000003381 stabilizer Substances 0.000 claims description 19
- 239000003549 soybean oil Substances 0.000 claims description 17
- 235000012424 soybean oil Nutrition 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 15
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 229960004488 linolenic acid Drugs 0.000 claims description 11
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 11
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 claims description 11
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 235000011803 sesame oil Nutrition 0.000 claims description 4
- 239000008159 sesame oil Substances 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 125000005481 linolenic acid group Chemical group 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 229940037312 stearamide Drugs 0.000 claims description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 description 26
- 229940090044 injection Drugs 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 238000009775 high-speed stirring Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000003022 colostrum Anatomy 0.000 description 12
- 235000021277 colostrum Nutrition 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229940095098 glycol oleate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Abstract
Description
实施例 | 粒径分布(95%) | 平均粒径 |
实施例1 | 190-290nm | 275nm |
实施例2 | 130-300nm | 232nm |
实施例3 | 150-250nm | 296nm |
实施例4 | 80-200nm | 153nm |
实施例5 | 50-150nm | 160nm |
实施例6 | 100-200nm | 180nm |
实施例 | 包封率 |
实施例1 | 98.7% |
实施例2 | 98.5% |
实施例3 | 98.2% |
实施例4 | 98.7% |
实施例5 | 99.0% |
实施例6 | 99.2% |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910475456.6A CN110123749B (zh) | 2019-06-03 | 2019-06-03 | 尼可地尔脂微球制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910475456.6A CN110123749B (zh) | 2019-06-03 | 2019-06-03 | 尼可地尔脂微球制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110123749A CN110123749A (zh) | 2019-08-16 |
CN110123749B true CN110123749B (zh) | 2022-01-25 |
Family
ID=67579884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910475456.6A Active CN110123749B (zh) | 2019-06-03 | 2019-06-03 | 尼可地尔脂微球制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110123749B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN87100285A (zh) * | 1986-01-17 | 1987-08-19 | 中外制药株式会社 | 生产稳定的尼柯地尔制剂的方法 |
EP0236679A1 (en) * | 1986-01-14 | 1987-09-16 | Chugai Seiyaku Kabushiki Kaisha | Nicorandil-containing preparation for injection |
EP0574221A1 (en) * | 1992-06-08 | 1993-12-15 | Therapicon Srl | Pharmaceutical stable formulations of nicorandil |
CN1562014A (zh) * | 2004-04-15 | 2005-01-12 | 沈阳药科大学 | 注射用ve烟酸酯乳剂及其制备方法 |
CN1813733A (zh) * | 2005-12-09 | 2006-08-09 | 唐星 | 维生素e烟酸酯脂质微球注射液及其制备方法 |
CN1839837A (zh) * | 2006-02-09 | 2006-10-04 | 西安力邦医药科技有限责任公司 | 尼可地尔冻干粉的制备方法 |
CN101716147A (zh) * | 2010-01-18 | 2010-06-02 | 北京泰德制药有限公司 | 一种前列地尔脂微球制剂 |
CN108078930A (zh) * | 2017-11-24 | 2018-05-29 | 扬子江药业集团北京海燕药业有限公司 | 一种注射用尼可地尔冻干粉针剂及其制备方法 |
-
2019
- 2019-06-03 CN CN201910475456.6A patent/CN110123749B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0236679A1 (en) * | 1986-01-14 | 1987-09-16 | Chugai Seiyaku Kabushiki Kaisha | Nicorandil-containing preparation for injection |
CN87100285A (zh) * | 1986-01-17 | 1987-08-19 | 中外制药株式会社 | 生产稳定的尼柯地尔制剂的方法 |
EP0574221A1 (en) * | 1992-06-08 | 1993-12-15 | Therapicon Srl | Pharmaceutical stable formulations of nicorandil |
CN1562014A (zh) * | 2004-04-15 | 2005-01-12 | 沈阳药科大学 | 注射用ve烟酸酯乳剂及其制备方法 |
CN1813733A (zh) * | 2005-12-09 | 2006-08-09 | 唐星 | 维生素e烟酸酯脂质微球注射液及其制备方法 |
CN1839837A (zh) * | 2006-02-09 | 2006-10-04 | 西安力邦医药科技有限责任公司 | 尼可地尔冻干粉的制备方法 |
CN101716147A (zh) * | 2010-01-18 | 2010-06-02 | 北京泰德制药有限公司 | 一种前列地尔脂微球制剂 |
CN108078930A (zh) * | 2017-11-24 | 2018-05-29 | 扬子江药业集团北京海燕药业有限公司 | 一种注射用尼可地尔冻干粉针剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Design and in vitro/in vivo evaluation of novel nicorandil;Ghada Ahmed Abdelbary;《European Journal of Pharmaceutics and Biopharmaceutics》;20080119;第69卷(第3期);第1019-1028页 * |
尼莫地平软胶囊稳定性的研究;刘 颖;《医学信息》;20140930;第27卷(第9期);第192-193页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110123749A (zh) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI362931B (en) | Irinotecan formulation | |
US9713591B2 (en) | Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same | |
CN104093399A (zh) | 鲁棒性控释肽制剂 | |
AU2007240317A1 (en) | Stable emulsion formulations | |
CN104755096B (zh) | 重构的hdl配制剂 | |
CN103520007A (zh) | 皮肤活性因子类柔性纳米脂质体及其制备方法和应用 | |
CN105431145B (zh) | 用于呋塞米的皮下施用的药物制剂 | |
CN104622806B (zh) | 一种丙泮尼地药物组合物及其制备方法 | |
Chen et al. | Long-lasting insulin treatment via a single subcutaneous administration of liposomes in thermoreversible pluronic® F127 based hydrogel | |
EP3957300A1 (en) | Cationic hyaluronic acid modified lipoid vesicle and preparation and application thereof | |
CN105287406B (zh) | 一种丙泊酚脂质体冻干制剂及其制备方法 | |
CN110123749B (zh) | 尼可地尔脂微球制剂及其制备方法 | |
CN102058531B (zh) | 一种脑保护治疗药物脂肪乳剂的制备 | |
JP2013540785A (ja) | 重合体のグアニジン誘導体を含んでいるリポソーム薬物組成物 | |
CN105919935A (zh) | 索拉非尼药物脂质纳米混悬剂及其制备方法 | |
US20140329774A1 (en) | Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparing method thereof | |
US20140212477A1 (en) | Hemoglobin-containing liposome and method for producing same | |
CN117357480B (zh) | 无针经皮注射用组合物 | |
JP5811421B2 (ja) | 保存効力を示す非水性油性注射用製剤 | |
CN103040764B (zh) | 一种盐酸平阳霉素脂质体注射剂 | |
CN116585304B (zh) | 一种急性肝损伤保护药物及其制备方法 | |
CN102247324A (zh) | 一种氟马西尼脂质体注射液 | |
EP3508214A1 (en) | Therapeutic agent for ischemic diseases | |
CN106176608A (zh) | 培美曲塞二钠注射剂及其制备方法 | |
AU2021104540A4 (en) | Sustained release liposomal delivery of Hydroxyurea in cancer treatment in vitro. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 100054 room b1307, 12 / F, building 21, Pingyuan Li, Xicheng District, Beijing Applicant after: Beijing preplus Biotechnology Co.,Ltd. Address before: 100054 room b1307, 12 / F, building 21, Pingyuan Li, Xicheng District, Beijing Applicant before: BEIJING PURUIBOSI INVESTMENT Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211015 Address after: 236800 5th floor, caohong Road comprehensive office building, high tech Zone, Bozhou City, Anhui Province Applicant after: Taiyangsheng (Bozhou) Biomedical Technology Co.,Ltd. Address before: 100054 room b1307, 12 / F, building 21, Pingyuan Li, Xicheng District, Beijing Applicant before: Beijing preplus Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nicorandil lipid microsphere preparation and its preparation method Effective date of registration: 20240102 Granted publication date: 20220125 Pledgee: Harbin Enterprise Credit Financing Guarantee Group Co.,Ltd. Pledgor: Taiyangsheng (Bozhou) Biomedical Technology Co.,Ltd. Registration number: Y2023990000644 |